CERS
What one share of Cerus holds
Surgical and Medical Instruments and Apparatus
We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.28 |
|---|---|
| Profit | −$0.03 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.01 |
| Cash and investments | $0.09 |
| Debt | $0.32 |
| Book value | $0.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.39 | −$0.62 | $0.01 | −$0.53 | — | $0.56 |
| 2017 | $0.47 | −$0.56 | $0.00 | −$0.49 | — | $0.34 |
| 2018 | $0.58 | −$0.44 | $0.01 | −$0.25 | — | $0.62 |
| 2019 | $0.67 | −$0.51 | $0.06 | −$0.53 | — | $0.40 |
| 2020 | $0.70 | −$0.37 | $0.01 | −$0.26 | — | $0.62 |
| 2021 | $0.93 | −$0.32 | $0.01 | −$0.20 | — | $0.49 |
| 2022 | $1.07 | −$0.24 | $0.01 | −$0.16 | — | $0.38 |
| 2023 | $1.04 | −$0.21 | $0.03 | −$0.27 | — | $0.29 |
| 2024 | $1.09 | −$0.11 | $0.02 | $0.05 | — | $0.30 |
| 2025 | $1.23 | −$0.08 | $0.02 | $0.01 | — | $0.33 |